Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women
- Conditions
- Obesity
- Interventions
- Dietary Supplement: ProbioticDietary Supplement: SymbioticDietary Supplement: Placebo
- Registration Number
- NCT02505854
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Brief Summary
The purpose of this study is to evaluate whether gut microbiota modulation by probiotic and symbiotic contribute with weight loss and improvement of metabolic parameters in women with obesity.
- Detailed Description
We will evaluate the effects of probiotic and symbiotic on weigh loss, blood glucose, lipid profile, metabolomic profile, and gut microbiota composition variables in women with obesity.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 32
- Women;
- Adult;
- Obese (BMI between 30 and 39,9 Kg/m²).
- Pregnancy or nursing;
- Smokers;
- Drinkers;
- Use of drug or phytotherapic;
- Diagnosis of any cronic disease;
- Daily consumption of yogurt.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Probiotic Probiotic Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin Symbiotic Symbiotic Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide Placebo Placebo Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
- Primary Outcome Measures
Name Time Method Evaluate the effect of probiotic and symbiotic on weight loss of women obese Baseline and 60 days and 15 days after the end of the intervention Determine and evaluate change in body weight and body mass index after intervention.
- Secondary Outcome Measures
Name Time Method Effect of probiotic and symbiotic on blood glucose Baseline, 60 days and 15 days after the end of the intervention Determine and comparing the blood glucose in plasma before and after intervention
Effect of probiotic and symbiotic on insulin resistance Baseline and 60 days Compare insulin resistance through HOMA-IR calculation before and after intervention and evaluate whether the intervention improvement in this parameter.
Effect of probiotic and symbiotic on metabolomic profile Baseline and 60 days Determine and comparing change in metabolomic profile before and after intervention. The metabolomic profile was evaluated in the serum of blood Bruker DRX 500 MHz equipment (Bruker Spectrospin, Karlsruhe, Germany) generating hydrogen isotope 1 (1H)-NMR spectra, that was compared to database Human Metabolome Data Base.
Effect of probiotic and symbiotic on lipid profile Baseline and 60 days Compare lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, very low-density lipoprotein, triglyceride) in serum of blood before and after intervention and evaluate whether the intervention improvement in this parameter.
Effect probiotic and symbiotic on blood pressure Baseline,60 days and 15 days after intervention conclusion Determine blood pressure and evaluate whether the intervention improvement blood pressure.
Effect of probiotic and symbiotic on gut microbiota composition Baseline, 60 days and 15 days after intervention conclusion Determine and comparing the amount filos (Fimicutes, Bacteroidetes, Actinobacteria, Verrucomicrobia e Proteobacteria) in gut microbiota and whether the change in microbiota composition continue after stop probiotic and symbiotic intake
Effect of probiotic and symbiotic on stool consitency by Bristol scale Baseline,60 days and 15 days after intervention conclusion Determine and comparing the stool consistency by Bristol scale. The Bristol scale is composed of 7 different stool consistency, being 1 and 2 lumpy, 3 and 4 normal, 5 to 7 loose.
Effect of probiotic and symbiotic on gastrointestinal symptons Baseline,60 days and 15 days after intervention conclusion Evaluate the presence of gastrointestinal symptoms related to the probiotic and symbiotic. The gastrointestinal symptoms analyzed were abdominal pains, abdominal distension and abdominal discomfort, flatus, borborygmus using the Likert scale of 5 point, which 0 is absence of symptom and 4 is every day.
Trial Locations
- Locations (1)
Louise Crovesy de Oliveira
🇧🇷Rio de Janeiro, Brazil